Enbrel, Prolia Suffer FDA’s Combination Punch On Device Components
This article was originally published in The Pink Sheet Daily
Amgen did not follow proper procedures when it switched from one Enbrel vial adapter to another, FDA says, a change that led to an uptick in product complaints.
You may also be interested in...
Amgen is making global changes to its internal inspection procedures in response to a warning letter from FDA
As sponsors and US FDA continue to face fallout, newly launched digital archive of industry documents from opioid litigation and settlements will be free public resource for those investigating activities that led to the opioid epidemic. It is modeled on the archive of tobacco industry documents, which has been the basis of about 1,000 scientific publications.
COVID-19 Therapeutic Trials: Investigators Should Join Forces Rather Than Conduct Single Site Studies
‘Treacherous combination’ of small clinical trials, lagging enrollment, unreported results and uncompleted trials is hindering COVID-19 research, former FDA Commissioner Califf says. Yale professor calls for a ‘Manhattan Project’ around knowledge and a change in the academic star system.